Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial

被引:222
作者
Shi, Yuankai [1 ,2 ]
Su, Hang [6 ]
Song, Yongping [7 ,8 ]
Jiang, Wenqi [9 ]
Sun, Xiuhua [10 ]
Qian, Wenbin [11 ]
Zhang, Wei [12 ]
Gao, Yuhuan [13 ]
Jin, Zhengming [14 ]
Zhou, Jianfeng [15 ]
Jin, Chuan [16 ]
Zou, Liqun [17 ]
Qiu, Lugui [3 ,4 ,5 ]
Li, Wei [18 ]
Yang, Jianmin [19 ]
Hou, Ming [20 ]
Zeng, Shan [21 ]
Zhang, Qingyuan [22 ]
Hu, Jianda [23 ]
Zhou, Hui [24 ]
Xiong, Yan [24 ]
Liu, Peng [1 ,2 ]
机构
[1] Chinese Acad Med Sci, Canc Hosp, Natl Clin Res Ctr Canc, Natl Canc Ctr, Beijing, Peoples R China
[2] Peking Union Med Coll, Beijing 100021, Peoples R China
[3] Chinese Acad Med Sci, Inst Haematol, Tianjin, Peoples R China
[4] Chinese Acad Med Sci, Blood Dis Hosp, Tianjin, Peoples R China
[5] Peking Union Med Coll, Tianjin, Peoples R China
[6] 307th Hosp Chinese Peoples Liberat Army, Dept Lymphoma, Beijing, Peoples R China
[7] Zhengzhou Univ, Affiliated Canc Hosp, Dept Haematol, Zhengzhou, Henan, Peoples R China
[8] Henan Canc Hosp, Zhengzhou, Henan, Peoples R China
[9] Sun Yat Sen Univ, Canc Ctr, Guangzhou, Guangdong, Peoples R China
[10] Dalian Med Univ, Hosp 2, Dept Oncol, Dalian, Liaoning, Peoples R China
[11] Zhejiang Univ, Affiliated Hosp 1, Dept Haematol, Hangzhou, Zhejiang, Peoples R China
[12] Peking Union Med Coll Hosp, Dept Haematol, Beijing, Peoples R China
[13] Hebei Med Univ, Dept Haematol, Hosp 4, Shijiazhuang, Hebei, Peoples R China
[14] Soochow Univ, Dept Haematol, Affiliated Hosp 1, Suzhou, Jiangsu, Peoples R China
[15] Huazhong Univ Sci & Technol, Tongji Hosp, Dept Haematol, Tongji Med Coll, Wuhan, Hubei, Peoples R China
[16] Guangzhou Med Univ, Canc Hosp, Dept Oncol, Guangzhou, Guangdong, Peoples R China
[17] Sichuan Univ, West China Hosp, Dept Oncol, Chengdu, Sichuan, Peoples R China
[18] Jilin Univ, Dept Oncol, Hosp 1, Changchun, Jilin, Peoples R China
[19] Changhai Hosp, Dept Haematol, Shanghai, Peoples R China
[20] Shandong Univ, Qilu Hosp, Dept Haematol, Jinan, Shandong, Peoples R China
[21] Cent S Univ, Dept Oncol, Xiangya Hosp, Changsha, Hunan, Peoples R China
[22] Harbin Med Univ, Canc Hosp, Dept Oncol, Harbin, Heilongjiang, Peoples R China
[23] Fujian Med Univ, Dept Haematol, Union Hosp, Fuzhou, Fujian, Peoples R China
[24] Innovent Biol Suzhou Co, Suzhou, Jiangsu, Peoples R China
来源
LANCET HAEMATOLOGY | 2019年 / 6卷 / 01期
关键词
BRENTUXIMAB VEDOTIN; BLOCKADE; PEMBROLIZUMAB; EXPRESSION; NIVOLUMAB; PD-L1;
D O I
10.1016/S2352-3026(18)30192-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Sintilimab (Innovent Biologics, Suzhou, China), a highly selective, fully humanised, monoclonal antibody, blocks the interaction between PD-1 and its ligands. We aimed to assess the activity and safety profile of sintilimab in Chinese patients with relapsed or refractory classical Hodgkin lymphoma. Pviethods In this ongoing, single-arm, phase 2 study, we recruited patients with histopathologically diagnosed classical Hodgkin lymphoma that was relapsed or refractory after two or more lines of therapy from 18 hospitals in China. Patients were given intravenous sintilimab (200 mg, once every 3 weeks) until progression, death, unacceptable toxicity, or withdrawal of consent. The primary outcome was the proportion of patients in the full analysis set (ie, those with classical Hodgkin lymphoma confirmed by the central pathology laboratory) who had an objective response, as assessed by an independent radiological review committee (IRRC), by 24 weeks after enrolment of the last patient. Tumour response was assessed by enhanced CT scan or MRI at baseline, at weeks 6, 15, and 24, every 12 weeks from weeks 24 to 48, and every 16 weeks beyond week 48. Safety was assessed in all treated patients. Findings Between April 19, 2017, and Nov 1, 2017, 96 patients were enrolled and commenced treatment. Four patients, whose diagnosis was not subsequently confirmed by the central pathology laboratory, were excluded from the full analysis set. Ten patients discontinued treatment. Median duration of follow-up was 10.5 months. In the full analysis set (n=92), 74 patients (80.4%; 95% CI 70.9-88.0) had an IRRC-assessed objective response before the analysis cutoff date of April 16, 2018. 89 (93%) of 96 patients had treatment-related adverse events, and 17 patients (18%) had grade 3 or 4 treatment-related adverse events, the most common being pyrexia (three [3%] patients). 14 (15%) patients had serious adverse events of any cause. No patient died during the study. Interpretation Sintilimab could be a new treatment option for patients with relapsed or refractory classical Hodgkin lymphoma in China. Copyright (C) 2019 Elsevier Ltd. All rights reserved.
引用
收藏
页码:E12 / E19
页数:8
相关论文
共 50 条
[11]   A Phase 2 Trial of Ibrutinib and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin's Lymphoma [J].
Hanel, Walter ;
Shindiapina, Polina ;
Bond, David A. ;
Sawalha, Yazeed ;
Epperla, Narendranath ;
Voorhees, Timothy ;
Welkie, Rina Li ;
Huang, Ying ;
Behbehani, Gregory K. ;
Zhang, Xiaoli ;
McLaughlin, Eric ;
Chan, Wing K. ;
Brammer, Jonathan E. ;
Jaglowski, Samantha ;
Reneau, John C. ;
Christian, Beth A. ;
William, Basem M. ;
Cohen, Jonathon B. ;
Baiocchi, Robert A. ;
Maddocks, Kami ;
Blum, Kristie A. ;
Alinari, Lapo .
CANCERS, 2023, 15 (05)
[12]   Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1-2 trial [J].
Davis, Kara L. ;
Fox, Elizabeth ;
Merchant, Melinda S. ;
Reid, Joel M. ;
Kudgus, Rachel A. ;
Liu, Xiaowei ;
Minard, Charles G. ;
Voss, Stephan ;
Berg, Stacey L. ;
Weigel, Brenda J. ;
Mackall, Crystal L. .
LANCET ONCOLOGY, 2020, 21 (04) :541-550
[13]   Phase 2 study of everolimus for relapsed or refractory classical Hodgkin lymphoma [J].
Johnston, Patrick B. ;
Pinter-Brown, Lauren C. ;
Warsi, Ghulam ;
White, Kristen ;
Ramchandren, Radhakrishnan .
EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2018, 7
[14]   Final results of a phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma [J].
Maruyama, Dai ;
Terui, Yasuhito ;
Yamamoto, Kazuhito ;
Fukuhara, Noriko ;
Choi, Ilseung ;
Kuroda, Junya ;
Ando, Kiyoshi ;
Hattori, Akira ;
Tobinai, Kensei .
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2020, 50 (11) :1265-1273
[15]   Circulating tumor DNA predicts response in Chinese patients with relapsed or refractory classical hodgkin lymphoma treated with sintilimab [J].
Shi, Yuankai ;
Su, Hang ;
Song, Yongping ;
Jiang, Wenqi ;
Sun, Xiuhua ;
Qian, Wenbin ;
Zhang, Wei ;
Gao, Yuhuan ;
Jin, Zhengming ;
Zhou, Jianfeng ;
Jin, Chuan ;
Zou, Liqun ;
Qiu, Lugui ;
Li, Wei ;
Yang, Jianmin ;
Hou, Ming ;
Xiong, Yan ;
Zhou, Hui ;
Du, Xinhua ;
Wang, Xiong ;
Peng, Bo .
EBIOMEDICINE, 2020, 54
[16]   Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial [J].
Armand, Philippe ;
Engert, Andreas ;
Younes, Anas ;
Fanale, Michelle ;
Santoro, Armando ;
Zinzani, Pier Luigi ;
Timmerman, John M. ;
Collins, Graham P. ;
Ramchandren, Radhakrishnan ;
Cohen, Jonathon B. ;
De Boer, Jan Paul ;
Kuruvilla, John ;
Savage, Kerry J. ;
Trneny, Marek ;
Shipp, Margaret A. ;
Kato, Kazunobu ;
Sumbul, Anne ;
Farsaci, Benedetto ;
Ansell, Stephen M. .
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (14) :1428-+
[17]   Real world effectiveness and safety of nivolumab in patients with relapsed or refractory classical hodgkin lymphoma [J].
Fernandez, Laura Lorente ;
Dominguez, Samuel Romero ;
Mari, Asuncion Albert ;
Benito, Esperanza Nunez ;
Briz, Eduardo Lopez ;
Andres, Jose Luis Poveda .
FARMACIA HOSPITALARIA, 2025, 49 (01) :17-23
[18]   Combination of acalabrutinib with lenalidomide and rituximab in relapsed/refractory aggressive B-cell non-Hodgkin lymphoma: a single-arm phase II trial [J].
Park, Changhee ;
Lee, Ho Sup ;
Kang, Ka-Won ;
Lee, Won-Sik ;
Do, Young Rok ;
Kwak, Jae-Yong ;
Shin, Ho-Jin ;
Kim, Sung-Yong ;
Yi, Jun Ho ;
Lim, Sung-Nam ;
Lee, Jeong-Ok ;
Yang, Deok-Hwan ;
Jang, Hun ;
Choi, Byoungsan ;
Lim, Jiwoo ;
Sun, Choong Hyun ;
Byun, Ja Min ;
Yoon, Sung-Soo ;
Koh, Youngil .
NATURE COMMUNICATIONS, 2024, 15 (01)
[19]   Safety and Efficacy of Tinostamustine in a Subpopulation of Patients With Relapsed/Refractory Hodgkin Lymphoma From a Phase I Trial [J].
Sureda, Anna ;
Pinto, Antonio ;
Ghesquieres, Herve ;
Morschhauser, Franck ;
Tournilhac, Olivier ;
Mutsaers, Pim ;
Zijlstra, Josee M. ;
De Filippi, Rosaria ;
Hilgier, Kasia ;
Manamley, Nick ;
Janik, Tomas ;
Zinzani, Pier Luigi .
HEMATOLOGICAL ONCOLOGY, 2025, 43 (01)
[20]   Selinexor in patients with relapsed or refractory diffuse large B -cell lymphoma (SADAL): a single -arm, multinational, multicentre, open -label, phase 2 trial [J].
Kalakonda, Nagesh ;
Maerevoet, Marie ;
Cavallo, Federica ;
Follows, George ;
Goy, Andre ;
Vermaat, Joost S. P. ;
Casasnovas, Olivier ;
Hamad, Nada ;
Zijlstra, Josee M. ;
Bakhshi, Sameer ;
Bouabdallah, Reda ;
Choquet, Sylvain ;
Gurion, Ronit ;
Hill, Brian ;
Jaeger, Ulrich ;
Manuel Sancho, Juan ;
Schuster, Michael ;
Thieblemont, Catherine ;
De la Cruz, Fatima ;
Egyed, Miklos ;
Mishra, Sourav ;
Offner, Fritz ;
Vassilakopoulos, Theodoros P. ;
Warzocha, Krzysztof ;
McCarthy, Daniel ;
Ma, Xiwen ;
Corona, Kelly ;
Saint-Martin, Jean-Richard ;
Chang, Hua ;
Landesman, Yosef ;
Joshi, Anita ;
Wang, Hongwei ;
Shah, Jatin ;
Shacham, Sharon ;
Kauffman, Michael ;
Van den Neste, Eric ;
Canales, Miguel A. .
LANCET HAEMATOLOGY, 2020, 7 (07) :E509-E522